{"title":"Nonlinear Model Predictive Control For Circadian Entrainment Using Small-Molecule Pharmaceuticals.","authors":"John H Abel, Ankush Chakrabarty, Francis J Doyle","doi":"10.1016/j.ifacol.2017.08.1596","DOIUrl":null,"url":null,"abstract":"<p><p>Recent <i>in vitro</i> studies have identified small-molecule pharmaceuticals effecting dose-dependent changes in the mammalian circadian clock, providing a novel avenue for control. Most studies employ light for clock control, however, pharmaceuticals are advantageous for clock manipulation through reduced invasiveness. In this paper, we employ a mechanistic model to predict the phase dynamics of the mammalian circadian oscillator under the effect of the pharmaceutical under investigation. These predictions are used to inform a constrained model predictive controller (MPC) to compute appropriate dosing for clock re-entrainment. Constraints in the formulation of the MPC problem arise from variation in the phase response curves (PRCs) describing drug effects, and are in many cases non-intuitive owing to the nonlinearity of oscillator phase response effects. We demonstrate through <i>in-silico</i> experiments that it is imperative to tune the MPC parameters based on the drug-specific PRC for optimal phase manipulation.</p>","PeriodicalId":74547,"journal":{"name":"Proceedings of the IFAC World Congress. International Federation of Automatic Control. World Congress","volume":"50 1","pages":"9864-9870"},"PeriodicalIF":0.0000,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034286/pdf/nihms-1688215.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the IFAC World Congress. International Federation of Automatic Control. World Congress","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ifacol.2017.08.1596","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/10/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Recent in vitro studies have identified small-molecule pharmaceuticals effecting dose-dependent changes in the mammalian circadian clock, providing a novel avenue for control. Most studies employ light for clock control, however, pharmaceuticals are advantageous for clock manipulation through reduced invasiveness. In this paper, we employ a mechanistic model to predict the phase dynamics of the mammalian circadian oscillator under the effect of the pharmaceutical under investigation. These predictions are used to inform a constrained model predictive controller (MPC) to compute appropriate dosing for clock re-entrainment. Constraints in the formulation of the MPC problem arise from variation in the phase response curves (PRCs) describing drug effects, and are in many cases non-intuitive owing to the nonlinearity of oscillator phase response effects. We demonstrate through in-silico experiments that it is imperative to tune the MPC parameters based on the drug-specific PRC for optimal phase manipulation.